BCG vaccine: a hope to control COVID-19 pandemic amid crisis.
Hum Vaccin Immunother
; 16(12): 2954-2962, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: covidwho-802179
ABSTRACT
COVID-19 caused by the virus SARS-CoV-2 has gripped essentially all countries in the world, and has infected millions and killed hundreds of thousands of people. Several innovative approaches are in development to restrain the spread of SARS-CoV-2. In particular, BCG, a vaccine against tuberculosis (TB), is being considered as an alternative therapeutic modality. BCG vaccine is known to induce both humoral and adaptive immunities, thereby activating both nonspecific and cross-reactive immune responses in the host, which combined could effectively resist other pathogens including SARS-CoV-2. Notably, some studies have revealed that SARS-CoV-2 infectivity, case positivity, and mortality rate have been higher in countries that have not adopted BCG vaccination than in countries that have done so. This review presents an overview of the concepts underlying BCG vaccination and its nonspecific immuological effects and protection, resulting in 'trained immunity' and potential utility for resisting COVID-19.
Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Vacina BCG
/
Reposicionamento de Medicamentos
/
Vacinas contra COVID-19
/
COVID-19
Tipo de estudo:
Estudo observacional
/
Ensaios controlados aleatorizados
Tópicos:
Vacinas
Limite:
Humanos
Idioma:
Inglês
Revista:
Hum Vaccin Immunother
Ano de publicação:
2020
Tipo de documento:
Artigo
País de afiliação:
21645515.2020.1818522
Similares
MEDLINE
...
LILACS
LIS